The eosinophil--quo vadis?

[1]  R. Thrall,et al.  Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat. , 2015, The American review of respiratory disease.

[2]  K. Dyer,et al.  Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. , 2003, Blood.

[3]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[4]  H. Hoogsteden,et al.  Airway Eosinophils Accumulate in the Mediastinal Lymph Nodes but Lack Antigen-Presenting Potential for Naive T Cells 1 , 2003, The Journal of Immunology.

[5]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[6]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[7]  R. Locksley,et al.  Helper T cells regulate type-2 innate immunity in vivo , 2002, Nature.

[8]  Lin Ying Liu,et al.  Decreased Expression of Membrane IL-5 Receptor α on Human Eosinophils: I. Loss of Membrane IL-5 Receptor α on Airway Eosinophils and Increased Soluble IL-5 Receptor α in the Airway After Allergen Challenge1 , 2002, The Journal of Immunology.

[9]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[10]  S. Phipps,et al.  The Relationship Between Allergen-Induced Tissue Eosinophilia and Markers of Repair and Remodeling in Human Atopic Skin1 , 2002, The Journal of Immunology.

[11]  P. Foster,et al.  Intrinsic Defect in T Cell Production of Interleukin (IL)-13 in the Absence of Both IL-5 and Eotaxin Precludes the Development of Eosinophilia and Airways Hyperreactivity in Experimental Asthma , 2002, The Journal of experimental medicine.

[12]  D. Dombrowicz,et al.  Eosinophils, allergy and parasites. , 2001, Current opinion in immunology.

[13]  M. Segal,et al.  Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. , 2001, The Journal of allergy and clinical immunology.

[14]  P. O'Byrne,et al.  The trials and tribulations of IL-5, eosinophils, and allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[15]  P. Foster,et al.  Eosinophils Promote Allergic Disease of the Lung by Regulating CD4+ Th2 Lymphocyte Function1 , 2001, The Journal of Immunology.

[16]  Yijun Fan,et al.  IL-12-Dependent Vascular Cell Adhesion Molecule-1 Expression Contributes to Airway Eosinophilic Inflammation in a Mouse Model of Asthma-Like Reaction1 , 2001, The Journal of Immunology.

[17]  A. McKenzie,et al.  Elemental signals regulating eosinophil accumulation in the lung , 2001, Immunological reviews.

[18]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[19]  D. Lúdvíksdóttir,et al.  Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. , 2000, American journal of respiratory and critical care medicine.

[20]  G. Gleich.  Mechanisms of eosinophil-associated inflammation. , 2000, The Journal of allergy and clinical immunology.

[21]  P. Weller,et al.  Lymph node trafficking and antigen presentation by endobronchial eosinophils. , 2000, The Journal of clinical investigation.

[22]  M. Humbert,et al.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.

[23]  G. Gleich,et al.  Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. , 1993, The Journal of clinical investigation.

[24]  G. Gleich,et al.  Hypereosinophilic syndrome: case presentation and update. , 2004, The Journal of allergy and clinical immunology.

[25]  M. Rothenberg.  Eosinophilic gastrointestinal disorders (EGID). , 2004, The Journal of allergy and clinical immunology.

[26]  J. Boyce,et al.  Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. , 2004, The Journal of allergy and clinical immunology.

[27]  T. Nutman,et al.  The role of eosinophils in host defense against helminth parasites. , 2004, The Journal of allergy and clinical immunology.

[28]  B. Bochner.  Verdict in the case of therapies versus eosinophils: the jury is still out. , 2004, The Journal of allergy and clinical immunology.